Research suppressed for seven years by drug companyBMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7088.1145 (Published 19 April 1997) Cite this as: BMJ 1997;314:1145
- Jacqui Wise
A drug company suppressed research which showed that generic thyroid drugs were as effective as its own branded product for almost seven years, says the Journal of the American Medical Association.
A randomised four way crossover trial concluded that two brand name and two generic forms of thyroxine sodium (levothyroxine) were bioequivalent and interchangeable without loss of therapeutic efficacy in most patients for the treatment of hypothyroidism (JAMA 1997;277:1205-18). The two brand name products were Synthroid–the most commonly used brand in the United States–and Levoxine (now renamed Levoxyl)–a newer, cheaper product similar in price to generic forms.
Thyroxine sodium is widely prescribed in the United States as the drug of choice for thyroid replacement treatment. The Food and Drug Administration (FDA) does not recognise thyroxine sodium products as bioequivalent, and generic substitution is not recommended. The authors of the study estimate that using generic or less expensive brand name products in the United States could save $356m (£223m) a year.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial